BELITE BIO, INC

Analyst Reco. Belite Bio, Inc

Equities

BLTE

US07782B1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
48.55 ^USD	-0.92%		-1.32%	+6.12%

Jun. 12	Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan	MT
Jun. 12	Belite Bio, Inc. Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Belite Bio Unveils Plan to Offer 651,380 American Depository Shares	Apr. 26	MT
Maxim Starts Coverage on Belite Bio with Buy Rating, $60 Price Target	Dec. 14	MT
HC Wainwright Raises Price Target on Belite Bio to $59 From $55, Maintains Buy Rating	Nov. 06	MT
Cantor Fitzgerald Initiates Belite Bio at Overweight Rating With $43 Price Target	23-07-28	MT
SVB Securities Starts Belite Bio at Outperform With $25 Price Target	23-07-26	MT
HC Wainwright Adjusts Belite Bio's Price Target to $55 From $58, Keeps Buy Rating	23-06-05	MT
HC Wainwright Initiates Coverage on Belite Bio With Buy Rating, $58 Price Target	22-08-01	MT
Benchmark Capital Initiates Belite Bio at Buy with $57 Price Target	22-07-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Secure my Investments

fermer